The evolution of colorectal cancer genetics-Part 1: From discovery to practice

Journal of Gastrointestinal Oncology

Volumn 5, Issue 5, 2014, Pages 326-335

  Schlussel, Andrew T ^a   Gagliano, Ronald A ^b   Seto Donlon, Susan ^a   Eggerding, Faye ^c   Donlon, Timothy ^d,e   Berenberg, Jeffrey ^a   Lynch, Henry T ^f  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^d Ohana Genetics   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer (CRC); CRC syndromes; Genetics; Lynch syndrome (LS); Prevention

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; DNA GLYCOSYLASE MUTY; EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

APC GENE; BRAF GENE; CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON POLYPOSIS; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; EPCAM GENE; EPIGENETICS; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GENE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MLH1 GENE; MORBIDITY; MSH2 GENE; MSH6 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTYH GENE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

EID: 84995783181     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2014.069     Document Type: Review

References (64)

1. Patel SG, Ahnen DJ. Familial colon cancer syndromes: An update of a rapidly evolving field. Curr Gastroenterol Rep 2012;14:428-38.
2. Classics in oncology. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the university of michigan, 1895-1913. By aldred scott warthin. 1913. CA Cancer J Clin 1985;35:348-59.
3. Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer 1971;27:1505-11.
4. Lynch HT, Harris RE, Lynch PM, et al. Role of heredity in multiple primary cancer. Cancer 1977;40:1849-54.
5. Fusaro RM, Lemon SJ, Lynch HT. Muir-torre syndrome and defective DNA mismatch repair genes. J Am Acad Dermatol 1996;35:493-4.
6. Yan H, Papadopoulos N, Marra G, et al. Conversion of diploidy to haploidy. Nature 2000;403:723-4.
7. Knudson AG Jr, Strong LC. Mutation and cancer: A model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972;48:313-24.
8. Knudson AG Jr. Heredity and human cancer. Am J Pathol 1974;77:77-84.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
10. Dukes C. The hereditary factor in polyposis intestini, or multiple adenomata. Cancer Rev 1930;5:241-55.
11. Gardner EJ, Woolf CM. Intestinal polyposis and carcinoma originating from a mutation in a family group. Cancer 1952;5:695-9.
12. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987;328:614-6.
13. Giardiello FM, Brensinger JD, Luce MC, et al. Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene. Ann Intern Med 1997;126:514-9.
14. Mecklin JP, Jarvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 finnish kindreds. Gastroenterology 1986;90:328-33.
15. Lynch HT, Watson P, Kriegler M, et al. Differential diagnosis of hereditary nonpolyposis colorectal cancer (lynch syndrome I and lynch syndrome II). Dis Colon Rectum 1988;31:372-7.
16. Vasen HF, Offerhaus GJ, den Hartog Jager FC, et al. The tumour spectrum in hereditary non-polyposis colorectal cancer: A study of 24 kindreds in the netherlands. Int J Cancer 1990;46:31-4.
17. Perea J, Justo I, Alvaro E, et al. Surgical management of hereditary colorectal cancer: Surgery based on molecular analysis and family history. Rev Esp Enferm Dig 2009;101:536-40.
18. Schrader K, Offit K, Stadler ZK. Genetic testing in gastrointestinal cancers: A case-based approach. Oncology 2012;26:433-6, 438, 444-6 passim.
19. Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000;47:43-9.
20. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30.
21. National society of genetic counselors. Available online: www.nsgc.org. Updated 20052014.
22. Rex DK, Johnson DA, Anderson JC, et al. American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-50.
23. Weissman SM, Burt R, Church J, et al. Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: National society of genetic counselors and the collaborative group of the americas on inherited colorectal cancer joint practice guideline. J Genet Couns 2012;21:484-93.
24. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: Colorectal (version 1.2014). National Comprehensive Cancer Network Web site. Available online: http://www.nccn.org. Updated 2014. Accessed 03/27, 2014.
25. Qureshi N, Carroll JC, Wilson B, et al. The current state of cancer family history collection tools in primary care: A systematic review. Genet Med 2009;11:495-506.
26. Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet 2004;41:81-91.
27. Rubin DT, Gandhi RK, Hetzel JT, et al. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci 2009;54:2473-83.
28. Domanska K, Carlsson C, Bendahl PO, et al. Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels. BMC Med Genet 2009;10:30.
29. Wong C, Gibbs P, Johns J, et al. Value of database linkage: Are patients at risk of familial colorectal cancer being referred for genetic counselling and testing? Intern Med J 2008;38:328-33.
30. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 2002;20:528-37.
31. Tyler CV Jr, Snyder CW. Cancer risk assessment: Examining the family physician's role. J Am Board Fam Med 2006;19:468-77.
32. Ait Ouakrim D, Boussioutas A, Lockett T, et al. Screening practices of unaffected people at familial risk of colorectal cancer. Cancer Prev Res (Phila) 2012;5:240-7.
33. Ladabaum U, Ferrandez A, Lanas A. Cost-effectiveness of colorectal cancer screening in high-risk spanish patients: Use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev 2010;19:2765-76.
34. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
35. Rees G, Martin PR, Macrae FA. Screening participation in individuals with a family history of colorectal cancer: A review. Eur J Cancer Care (Engl) 2008;17:221-32.
36. Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005;331:1047.
37. Australian institute of health and welfare. Cancer --Australian cancer statistics update May 2010. AIHW. 2010.
38. Ferlay J, Bray F, Forman D, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase no. 10. Lyon, France: International Agency for Research on Cancer Web site. Available online: http://wwwdep. iarc.fr. Updated 20102012.
39. Schattner A, Gilad A. Primary care physicians' awareness and implementation of screening guidelines for colorectal cancer. Prev Med 2002;35:447-52.
40. Giveon S, Kahan E. Patient adherence to family practitioners' recommendations for breast cancer screening: A historical cohort study. Fam Pract 2000;17:42-5.
41. Snell JL, Buck EL. Increasing cancer screening: A meta analysis. Prev Med 1996;25:702-7.
42. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
43. Shi C, Washington K. Molecular testing in colorectal cancer: diagnosis of lynch syndrome and personalized cancer medicine. Am J Clin Pathol 2012;137:847-59.
44. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-18.
45. Lynchx HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
46. Iyer RR, Pluciennik A, Burdett V, et al. DNA mismatch repair: Functions and mechanisms. Chem Rev 2006;106:302-23.
47. Larrea AA, Lujan SA, Kunkel TA. SnapShot: DNA mismatch repair. Cell 2010;141:730.e1
48. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010;107:6982-7.
49. Hegde M, Ferber M, Mao R, et al. Working Group of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med 2014;16:101-16.
50. Kuiper RP, Vissers LE, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in lynch syndrome. Hum Mutat 2011;32:407-14.
51. Umar A, Risinger JI, Hawk ET, et al. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 2004;4:153-8.
52. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletionpositive lynch syndrome: A cohort study. Lancet Oncol 2011;12:49-55.
53. Sijmons RH, Greenblatt MS, Genuardi M. Gene variants of unknown clinical significance in lynch syndrome. An introduction for clinicians. Fam Cancer 2013;12:181-7.
54. Barrero MJ, Boue S, Izpisua Belmonte JC. Epigenetic mechanisms that regulate cell identity. Cell Stem Cell 2010;7:565-70.
55. Peltomäki P. Epigenetic mechanisms in the pathogenesis of lynch syndrome. Clin Genet 2014;85:403-12.
56. Hitchins MP. The role of epigenetics in lynch syndrome. Fam Cancer 2013;12:189-205.
57. Hampel H. Point: Justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 2010;8:597-601.
58. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000;18:1967-79.
59. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001;10:721-33.
60. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
61. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
62. Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 2014;5:40-9.
63. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
64. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.